BriaCell Therapeutics Corp. (BCTX) Cash Flow Statement
Where BCTX’s cash came from and went, FY2025
July 31, 2025 · U.S. dollars- Cash from operations
- −$39.1M
- Capital expenditures
- $3
- Free cash flow
- −$39.1M
- Returned to shareholders
- —
- Change in cash
- $13.2M cash at year-end $14.4M
Drawn to scale: where the cash came from and how it was used. Hover for values.
BCTX operating cash flow, capex and free cash flow
BCTX cash flow trends, FY2016–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$1.6MFY2016 | −$39.1MFY2025 | — | |
| Capital expenditures | $3FY2016 | $3FY2025 | +0.2%/yr | |
| Free cash flow | −$1.6MFY2016 | −$39.1MFY2025 | — | |
| Stock-based compensation | $496,209FY2016 | $776,879FY2025 | +5.1%/yr | |
| Share buybacks (net) | $0FY2021 | $0FY2024 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BCTX cash flow by activity
BCTX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
BCTX cash flow statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$36.5M | −$6.5M | −$27.3M | −$34.1M | −$17.6M | −$4.9M | −$5.8M | −$5.4M | −$3.2M | −$2.2M |
| Depreciation & amortization | $107,334 | $83,897 | $15,271 | $15,272 | $19,462 | $18,735 | $18,833 | $16,877 | $290 | $1,803 |
| Stock-based compensation | $776,879 | $1.8M | $2.2M | $3.1M | $2.0M | $1,686 | $46,075 | $365,492 | $218,248 | $496,209 |
| Change in working capital | −$2.6M | $9.6M | −$4.7M | −$497,542 | −$2.9M | $3.3M | $1.0M | −$466,675 | $1.0M | −$28,993 |
| Other non-cash items | −$816,793 | −$37.9M | −$2.1M | $15.7M | $8.7M | $87,092 | −$407,814 | $537,957 | $53,490 | $184,428 |
| Cash from operating activities | −$39.1M | −$33.0M | −$31.9M | −$15.9M | −$9.9M | −$1.6M | −$5.1M | −$5.0M | −$1.9M | −$1.6M |
| Investing activities | ||||||||||
| Capital expenditures | −$3 | −$624,208 | −$4 | $0 | −$4 | $0 | −$5 | −$3 | −$4 | −$3 |
| Investments (net) | — | −$681,801 | $0 | — | $0 | $30,958 | $1.3M | −$591,043 | $150,000 | — |
| Acquisitions & other investing | −$10.6M | $374,343 | — | — | — | −$30,958 | $6,492 | $550 | −$149 | $208,984 |
| Cash from investing activities | −$10.6M | −$931,666 | — | — | — | $0 | $1.3M | −$590,496 | $149,847 | $208,981 |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | — | $0 | −$63,518 | −$12.9M | $0 | — | — | — | — | — |
| Net borrowing (repayment) | — | — | — | $0 | −$332,935 | $27,600 | −$117,540 | $673,070 | $673,070 | — |
| Shares issued | $0 | $4.4M | $4.0M | $21.9M | $51.6M | $1.1M | $2.3M | $0 | $0 | $0 |
| Other financing | $63.0M | $1.6M | $1.4M | −$13.7M | $31.6M | $359,766 | $866,597 | $4.6M | $2.2M | $1.1M |
| Cash from financing activities | $63.0M | $6.0M | $5.3M | −$4.8M | $82.9M | $1.4M | $3.0M | $5.3M | $2.9M | $1.1M |
| Summary | ||||||||||
| Net change in cash | $13.2M | −$28.2M | −$26.3M | −$20.8M | $71.5M | −$170,632 | −$757,215 | −$377,652 | $1.1M | −$296,217 |
| Cash at end of period | $14.4M | $1.2M | $28.0M | $52.7M | $71.6M | $26,095 | $193,848 | $937,580 | $1.3M | $173,176 |
| Free cash flow | −$39.1M | −$33.6M | −$31.9M | −$15.9M | −$9.9M | −$1.6M | −$5.1M | −$5.0M | −$1.9M | −$1.6M |
| Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | Jul '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$7.2M | −$7.3M | −$11.4M | −$11.1M | −$8.7M | −$9.1M | −$7.9M | −$1.7M | $2.3M | −$15.3M | $8.1M | −$3.2M |
| Depreciation & amortization | $33,010 | $26,657 | $26,657 | $36,427 | $37,922 | $38,398 | $36,350 | $99,742 | $5,137 | $5,163 | $5,134 | $5,099 |
| Stock-based compensation | $432,207 | $285,856 | $294,686 | — | $224,815 | $285,093 | $266,971 | $377,892 | $392,215 | $500,155 | $533,816 | $533,816 |
| Change in working capital | $91,453 | −$922,621 | $315,867 | $572,507 | −$1.5M | $1.2M | −$2.9M | $1.8M | $5.0M | $2.5M | $242,525 | −$5.3M |
| Other non-cash items | −$396,179 | −$60,297 | $46,530 | −$755,676 | −$137,006 | −$983,007 | $998,562 | −$6.3M | −$14.5M | $2.3M | −$19.1M | −$6.7M |
| Cash from operating activities | −$7.1M | −$8.0M | −$10.7M | −$11.2M | −$10.1M | −$8.6M | −$9.5M | −$5.7M | −$6.8M | −$10.0M | −$10.2M | −$14.7M |
| Investing activities | ||||||||||||
| Capital expenditures | −$129,176 | −$4 | −$4 | −$3 | −$4 | $0 | $0 | −$624,206 | $0 | $0 | −$4 | $0 |
| Investments (net) | −$15.8M | — | — | — | −$105,000 | −$75,000 | −$75,000 | −$456,801 | −$225,000 | $0 | $0 | — |
| Acquisitions & other investing | −$388,335 | $7.3M | −$104,061 | −$10.3M | −$42,897 | −$32,972 | −$27,275 | $455,234 | −$76,795 | — | — | — |
| Cash from investing activities | −$16.3M | $7.3M | −$104,065 | −$10.3M | −$147,901 | −$107,972 | −$102,275 | −$625,773 | −$301,795 | — | — | — |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | $0 | $0 | $0 | $0 | −$116 |
| Shares issued | $0 | $27.9M | $0 | $0 | $14.7M | $4.7M | $11.7M | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$108,646 | $0 | $0 | $18.7M | $6.0M | $3.0M | $4.6M | $6.0M | $0 | $0 | $0 | $5.4M |
| Cash from financing activities | −$108,646 | $27.9M | $0 | $18.7M | $20.7M | $7.7M | $16.3M | $6.0M | $0 | $0 | $0 | $5.4M |
| Summary | ||||||||||||
| Net change in cash | −$22.8M | $27.2M | −$10.9M | −$2.8M | $10.3M | −$1.2M | $6.9M | −$98,000 | −$7.2M | −$10.0M | −$10.4M | −$9.2M |
| Cash at end of period | $6.9M | $29.9M | $3.8M | $14.4M | $17.2M | $7.4M | $8.1M | $1.2M | $1.3M | $8.3M | $18.8M | $28.0M |
| Free cash flow | −$7.2M | −$8.0M | −$10.7M | −$11.2M | −$10.1M | −$8.6M | −$9.5M | −$6.3M | −$6.8M | −$10.0M | −$10.2M | −$14.7M |
| Free cash flow margin | — | — | — | −4,972.0% | — | — | — | −27,694.7% | — | — | — | — |
| Capex / revenue | — | — | — | 0.0% | — | — | — | 2,753.3% | — | — | — | — |
| Operating cash flow / net income | — | — | — | — | — | — | — | — | −2.94 | — | −1.27 | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
BCTX cash generation
In fiscal 2025 (ended July 31, 2025), BriaCell Therapeutics generated -$39.1 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$39.1 million. Cash and equivalents rose by $13.2 million over the year.
Related: BCTX income statement, BCTX balance sheet. See the BCTX stock overview for the latest quote and news.
BCTX cash flow FAQ
What is BriaCell Therapeutics's free cash flow?
BriaCell Therapeutics's free cash flow was -$39.1 million in fiscal 2025: -$39.1 million of operating cash flow minus $0.0 million of capital expenditures It was -$33.6 million a year earlier..
How much cash does BriaCell Therapeutics generate from operations?
BriaCell Therapeutics generated -$39.1 million of cash from operating activities in fiscal 2025.
How much does BriaCell Therapeutics spend on capital expenditures?
BriaCell Therapeutics spent $0.0 million on capital expenditures in fiscal 2025, compared with $0.6 million the year before.